RACHAEL FINLAND: Open Payments
NPI 1538756143 · DU BOIS, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$946 in 53 payments from 28 companies in 2025. Trend: 2023 $522 · 2024 $884 · 2025 $946
Food & beverage: $946
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $146 |
| Daiichi Sankyo Inc. | 4 | $86 |
| Genentech USA, Inc. | 4 | $64 |
| Novartis Pharmaceuticals Corporation | 3 | $53 |
| Lilly USA, LLC | 2 | $50 |
| Rigel Pharmaceuticals, Inc. | 3 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $40 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Genmab U.S., Inc. | 2 | $36 |
Products named: VERZENIO, TAVALISSE, REXULTI, EMRELIS, ORGOVYX, SCEMBLIX, DATROWAY, Epkinly.
Industry payments across PA — which companies pay providers there.
